文献速递腹部介入CTMR

LI-RADS 局部治疗反应标准的诊断准确性:系统评价与Meta分析

Diagnostic accuracy of Liver Imaging Reporting and Data System locoregional treatment response criteria: a systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2021-03-30

该系统评价与Meta分析共纳入4项研究、462个LR-TR观察(240例患者,82.5%男性),以移植病理为参考标准。LR-TR标准诊断存活肿瘤的合并敏感度为62%(95%CI 49-74%)、特异度为87%(95%CI 76-93%),AUC为0.80。结论认为LR-TR标准对局部治疗后存活肿瘤具有可接受的诊断性能。

要点

  • LR-TR诊断存活肿瘤特异度87%高于敏感度62%,阳性判断较可靠,阴性不能排除存活肿瘤。
  • LR-TR的合并AUC为0.80,诊断比值比9.83,整体诊断性能可接受。
  • 阅片者间一致性为中等至良好,但仍需关注可疑(equivocal)病灶的判读。

核心结论

  • LI-RADS LR-TR标准对局部治疗后存活肿瘤具有可接受的诊断性能,合并敏感度62%、特异度87%、AUC 0.80。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase、Scopus和Cochrane Central Register of Controlled Trials至2020年6月30日,最终纳入4项研究。
  • 共462个LR-TR观察、240例患者,82.5%为男性,参考标准为移植切除标本的组织病理学。
  • 纳入研究涵盖单纯栓塞、化疗栓塞、射频消融和微波消融等不同局部治疗方式,局部治疗至肝移植的平均间隔为181至219天。
  • 采用QUADAS-2工具评价纳入研究的质量。

诊断标准与关键数值

  • LR-TR标准诊断存活肿瘤的合并敏感度为62%(95%CI 49-74%;I2=69%),合并特异度为87%(95%CI 76-93%;I2=57%)。
  • 合并诊断比值比为9.83(95%CI 5.34-18.08;I2=19%),合并AUC为0.80。
  • LR-TR标准的阅片者间一致性为中等至良好。

临床应用与阅片要点

  • 报告局部治疗后病灶时按LR-TR分类描述,存活肿瘤判断阳性时特异度较高,可支持临床决策。
  • 因敏感度仅62%,LR-TR阴性或可疑病灶不能排除存活肿瘤,需结合随访增强扫描动态观察。
  • 不同局部治疗方式(栓塞、消融等)均纳入分析,判读时应结合具体治疗类型理解标准表现。

局限性

  • 仅纳入4项研究,证据量有限,且为基于移植病理的回顾性诊断准确性研究汇总。
  • 各研究间敏感度存在中度异质性(I2=69%),原文指出需设计良好的前瞻性研究评价可疑病灶标准及不同局部治疗方式的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: There is increasing adoption of Liver Imaging Reporting and Data System (LI-RADS) treatment response (LR-TR) criteria. However, there is still a relative lack of evidence evaluating the performance of these criteria. We performed this study to assess the diagnostic accuracy of LI-RADS LR-TR criteria.

METHODS: A thorough search of PubMed, Embase, Scopus, and Cochrane Central Register of Controlled Trials for studies reporting diagnostic accuracy of LI-RADS LR-TR criteria was conducted through 30 June 2020. The meta-analytic summary of sensitivity, specificity, and diagnostic odds ratio of LI-RADS LR-TR criteria was computed using explant histopathology as the reference standard. The quality of the studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool.

RESULTS: Four studies were found eligible for meta-analysis. The total number of LR-TR observations was 462 (240 patients, 82.5% males). Different locoregional therapies (LRTs), including bland embolization, chemoembolization, radiofrequency ablation, and microwave ablation, had been used. The mean time interval between LRT and liver transplantation ranged from 181 to 219 days. There was a moderate to good inter-reader agreement for LR-TR criteria. The pooled sensitivity and specificity of LR-TR criteria for viable disease were 62% (95% CI, 49-74%; I2 = 69%) and 87% (95% CI, 76-93%; I2 = 57%), respectively. The pooled diagnostic odds ratio and area under the curve were 9.83 (95% CI, 5.34-18.08; I2 = 19%) and 0.80.

CONCLUSIONS: LI-RADS LR-TR criteria have acceptable diagnostic performance for the diagnosis of viable tumor after LRT. Well-designed prospective studies evaluating criteria of equivocal lesions and effect of different LRTs should be performed.

KEY POINTS: • The pooled sensitivity and specificity of LI-RADS LR-TR criteria for the diagnosis of viable tumor were 62% and 87%, respectively. • The pooled diagnostic odds ratio and area under the curve were 9.83 and 0.80. • LR-TR criteria had a moderate to good inter-reader agreement.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Gupta P, Bansal A, Das GC, et al. Diagnostic accuracy of Liver Imaging Reporting and Data System locoregional treatment response criteria: a systematic review and meta-analysis. Eur Radiol. 2021. PMID: 33786656. doi:10.1007/s00330-021-07837-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。